OPR 003

Drug Profile

OPR 003

Alternative Names: Anti-IL-6 mAb (OP-R003-1, 1339) - Vaccinex; Azintrel; mAb 1339; OP-R003; VX 30

Latest Information Update: 08 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaccinex
  • Developer EUSA Pharma; Vaccinex
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haematological malignancies; Rheumatoid arthritis

Most Recent Events

  • 08 Oct 2015 Discontinued - Phase-I for Haematological malignancies in USA (Parenteral)
  • 08 Oct 2015 Discontinued - Phase-I for Rheumatoid arthritis in USA (Parenteral)
  • 12 Jun 2012 EUSA Pharma has been acquired by Jazz Pharmaceuticals plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top